Article summary:
A recent clinical trial revealed potential effects of Vitamin C on patients suffering from blood disorders that may turn into cancer. Although the vitamin did not affect the speed of abnormal cell growth, it was associated with improvements in inflammation markers and a reduction in serious complications such as anemia and infections, in addition to a possible increase in survival rates. These findings point to the importance of further studies to test the benefits of Vitamin C in prevention or early intervention for the treatment of blood diseases.
🧬 New study links Vitamin C to disease improvements in blood disorders
Vitamin C has become one of the popular dietary supplements, but its role in modifying cellular protein activity, such as TET enzymes, makes it a focus of scientific attention in recent medical research.
These enzymes control the switching on and off of important genes for cell health. It is known that reduced activity of these enzymes increases the risk of developing certain types of blood cancer.
As a result, a team of researchers conducted a phase two clinical trial to examine the possibility of using Vitamin C to improve the condition of patients suffering from blood disorders that may progress to cancer, or those who have low-risk blood cancers.
🧪 Trial design and objectives
The clinical trial, called the EVITA trial, involved 109 patients in both Denmark and the United States, who were suffering from blood disorders with the potential to become cancer, or low-risk blood cancers.
The researchers divided the participants randomly and in a double-blind manner into two groups; 55 people received Vitamin C supplements at a daily dose of 1000 mg, and 54 people received a placebo (placebo).
The study used 12 months of monitoring to determine the supplement’s effect on the growth rate of abnormal cells.
🩺 Main results and health effects
Vitamin C did not show a change in the growth rate of abnormal blood cells compared with the group that received the placebo.
But positive changes were observed in the body’s inflammation markers among Vitamin C users, in addition to a decrease in the occurrence of some serious complications, as follows:
- A lower rate of anemia (anemia).
- A decrease in cases of pneumonia (pneumonia).
- Fewer cases of acute aseptic arthritis (acute aseptic arthritis).
- A reduction in internal bleeding.
On the other hand, the Vitamin C group recorded a higher rate of digestive problems.
🧠 A possible signal of long-term survival benefits
After a follow-up period averaging 33.6 months (about 3 years), 35 participants had died; 24 of them were from the placebo group compared with 11 in the Vitamin C group.
An initial exploratory analysis showed the possibility of a positive effect of the vitamin on survival rates compared with the other group, despite the rarity of deaths.
However, the researchers confirmed that these findings need to be verified in expanded clinical trials (phase three) before being confirmed or adopted clinically.
🌱 Explanations and implications of future findings
Professor Peter Jones, one of the participating researchers, stated that the trial results provide strong scientific reasons to continue studying Vitamin C as a potential supplement, especially in the early stages of blood disorders.
These important observations reflect its role in modulating inflammatory responses through its effect on TET enzymes, which may delay or prevent progression to serious cancerous conditions.
🧬 The need for larger and more precise studies
Physician and researcher Kirsten Gronbak confirmed that these results are promising but not sufficient at present to make treatment decisions based on them.
As a result, it is necessary to conduct broader clinical trials involving a larger number of patients to more precisely assess the extent of Vitamin C’s effect and to clarify its mechanism of action and long-term safety.
This trial highlights the growing importance of understanding the relationships between nutrition, cellular metabolism, and gene regulation, and their potential impact on preventing or improving complex diseases such as blood cancer.
🩺 Conclusion and scientific recommendations
In this trial, Vitamin C provides a vital example of how a dietary supplement can affect molecular biological processes and strengthen the body’s immunity against multiple health complications.
Nevertheless, these findings should be treated with caution and direct treatment recommendations should not be drawn without completing large-scale trials and medical supervision.
Understanding the role of vitamins, including Vitamin C, in modifying TET enzyme activity and inflammatory pathways remains among the promising areas of research that may contribute in the future to cancer prevention strategies.
📚 Related articles
Discover more from Mohdbali
Subscribe to get the latest posts sent to your email.
